Search

Evacuation planning problem can be considered as a dynamic flow problem on the dynamic network. In a dangerous situation, as many individuals as possible should be rescued from a dangerous zone to a safety zone as quickly and efficiently as possible. The earliest arrival flow problem is to send a maximal amount of dynamic flow reaching the safety zone sink not only for the given time horizon, but also for any earlier moment of the time horizon. In this paper we discuss the optimization formulation of the earliest arrival evacuation planning problem with efficient solution procedure.Journal of Advanced College of Engineering and Management, Vol. 2, 2016, page: 57-62

The general industrial regulator problem has been formulated in mathematical terms. The regulator theory developed draws upon the dual property of controllability and observability of the system and uses pole assignment technique as mathematical tool for designing the regulator. The disturbance rejection property is in-built into the regulator. A combination of state feedback and integral control along with feed-forward from changing reference and/or disturbance signals achieve regulation and/or tracking. The total control law so obtained can be implemented by means of a microprocessor based programmable controller.

The significant insights into the immunobiology of central nervous system (CNS) and brain tumor have opened up the feasibility of applying 'Immunotherapy' as an alternative to the poor prognosis of malignant brain tumor with conventional therapeutic approaches. Though cytokines like IL-2 and IFN-gamma used against glioma showed some favorable results by eliciting Th1 type immune response, a proper immunotherapeutic agent is still to be searched for. Sheep erythrocyte (SRBC), a corpuscular antigen showed a better therapeutic efficacy in terms of enhanced survival and augmentation of cell mediated immunity (CMI) in a glioma model developed by chemical carcinogen ethyl nitrosourea. Histological findings revealed most efficient glioma rejection in SRBC and combination biological response modifier (BRM) treated groups. Simultaneously E-rosetting, cytotoxicity of lymphocytes, phagocytosis and antigen presenting capacity of myeloid cells established the better therapeutic efficacy of SRBC alone than other BRMs viz. IL-2 and IFN-gamma. Even the effect of combination therapy of different BRMs showed marginal differences in facilitating glioma reduction than the single use of SRBC. These findings emphasized the application of SRBC as an exogenous BRM having the potential as a rational therapeutic adjunct against glioma.